Nicox : Suggested agenda and summary of the resolutions submitted to the approval of the Ordinary shareholder meeting 2023 (translation for information purpose)
January 09, 2023 at 06:59 am EST
Share
NICOX SA
AGENDA AND DRAFT RESOLUTIONS
ORDINARY SHAREHOLDER MEETING
CONVENED ON FEBRUARY 14, 2023
(AND ON SECOND CALL ON FEBRUARY 28, 2023)
Agenda of the ordinary shareholder meeting
Approval of the plan to transfer the listing of shares issued by the Company from compartment C of the Euronext Paris regulated market to the Euronext Growth Paris multilateral trading system (resolution 1).
Power for legal formality requirements (resolution 2).
DRAFT RESOLUTIONS
First resolution - Approval of the plan to transfer the listing of shares issued by the Company from compartment C of the Euronext Paris regulated market to the Euronext Growth Paris multilateral trading system
The Shareholder Meeting, deliberating under the quorum and majority conditions required for ordinary general meetings, having considered the report of the Board of Directors:
approves, in accordance with the legal and regulatory provisions in force, and in particular those of Article L. 421-14 of the French Monetary and Financial Code, the proposed transfer of the listing of the shares issued by the Company from compartment C of the Euronext Paris regulated market to the Euronext Growth Paris multilateral trading system within twelve (12) months from the date of this General Meeting;
authorizes, therefore, the proposed request for the delisting of the shares issued by the Company from compartment C of the Euronext Paris regulated market and their concomitant admission to trading on the Euronext Growth Paris multilateral trading system (the "Transfer");
delegates all powers to the Board of Directors, with the option of sub-delegation under the conditions provided for by law, to carry out the Transfer within a period of twelve (12) months from this General Meeting, subject to the agreement of Euronext Paris, and in particular to request the admission to trading of the Company's shares on the Euronext Growth Paris multilateral trading system and their simultaneous delisting from compartment C of the Euronext Paris regulated market, prepare the information document required under the rules Euronext Growth, choose a Listing Sponsor, give all warranties, make all declarations, carry out all formalities including advertising, and more generally take all necessary measures for the effective completion of the Transfer.
Second resolution - Power for legal formality requirements
The General Meeting grants all powers to the bearer of a copy or an extract of the minutes hereof for the purpose of carrying out the legal formalities.
2
Attachments
Original Link
Original Document
Permalink
Disclaimer
NicOx SA published this content on 09 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2023 11:58:11 UTC.
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The Company is also conducting research on NCX 1728 in retinal conditions. NCX 4251 for topical ocular application for dry eye disease is being developed by Nicox's licensed partner Ocumension Therapeutics in China and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow Health, Inc. in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets."
Nicox : Suggested agenda and summary of the resolutions submitted to the approval of the Ordinary shareholder meeting 2023 (translation for information purpose)